Clinical Trial Update: Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study [Phase 1]

View source ↗

Summary

Phase 1 pilot study evaluating ixazomib with dexamethasone in patients with high-risk smoldering myeloma and multiple myeloma; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma
• Smoldering Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• NINLARO (ixazomib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Multiple Myeloma, High Risk Smoldering Multiple Myeloma | Phase 1 | Status: COMPLETED